Asset Details
Do you wish to reserve the book?
OM‐85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
OM‐85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study
Do you wish to request the book?
OM‐85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
OM‐85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study
2025
Overview
Introduction The current clinical management of pulmonary nodules relies heavily on CT follow‐up, without early intervention. This retrospective study investigated the efficacy of OM‐85, a standardized lysate of human respiratory bacteria, in the treatment of high‐risk pulmonary nodules detected by computed tomography (CT) in patients with chronic bronchitis. Methods This study included 72 patients (93 enrolled nodules) who underwent treatment with OM‐85 and a matched control group of 90 patients (111 control nodules). The primary endpoint included reduced size of high‐risk ground glass nodules based on thin‐layer CT scans during follow‐up. Flow cytometry, multiplex immunofluorescence (mIF) analysis, and scRNA‐seq data were employed to determine differences in the immune cell subsets between the treatment and control groups. Results Oral OM‐85 treatment significantly reduced lung nodule diameter (p = 0.031), the risk probability of malignancy (p = 0.003), and the likelihood of clinical disease progression (p = 0.0091). The effects of OM‐85 treatment were more pronounced in older patients (> 65‐year‐old) (p = 0.029) and those with longer follow‐up cycles (> 200 days) (p = 0.011). The peripheral blood samples showed a significantly higher proportion of natural killer (NK) cells in the treatment group. Furthermore, mIF staining of the pulmonary nodules and scRNA‐seq data demonstrated a higher percentage of NK cells in the treatment group compared with the control group (p = 0.0003). Conclusion OM‐85 reduced the size of high‐risk pulmonary nodules and decreased the risk of malignant probability and disease progression in patients with chronic bronchitis by increasing the proportion of NK cells. Therefore, OM‐85 is a potential drug for the treatment of high‐risk pulmonary nodules in patients with chronic bronchitis. OM‐85 reduced the size of high‐risk pulmonary nodules and decreased the risk of malignant probability and disease progression by increasing the proportion of NK cells. Therefore, OM‐85 may be a potential agent for the treatment of high‐risk pulmonary nodules.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Aged
/ Bronchitis, Chronic - complications
/ Cell Extracts - administration & dosage
/ Cell Extracts - therapeutic use
/ Female
/ Humans
/ Lung Neoplasms - prevention & control
/ Male
/ Multiple Pulmonary Nodules - diagnostic imaging
/ Multiple Pulmonary Nodules - drug therapy
/ Multiple Pulmonary Nodules - pathology
/ OM‐85
/ Original
/ Solitary Pulmonary Nodule - diagnostic imaging
/ Solitary Pulmonary Nodule - drug therapy
/ Solitary Pulmonary Nodule - pathology
